Expert Interview
A second look: Discussing the potential of Odronextamab, a CD20xCD3 bispecific antibody and the results from it's Phase II ELM-2 study in patients with Relapsed/Refractory DLBCL highlighted at ASH 2022
Ticker(s): REGNInstitution: Columbia University Medical Center
- Lead investigator of the Phase 1b/2a study for AFM13.
- Treats 50 active PTCL patients and consults on 20 additional patients.
- Author on 30 peer reviewed articles and participated in 2 clinical trials in the past 15 years
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
